Continuation of the Collaborative Islet Transplantation Registry (U01 Clinical Trial Not allowed)
ID: 360637Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/360637
Timeline
    Description

    The National Institutes of Health (NIH) is preparing to release a Notice of Funding Opportunity (NOFO) for the continuation of the Collaborative Islet Transplantation Registry (CITR), aimed at collecting and analyzing data from clinical trials involving isolated human islets as a treatment for diabetes. This initiative seeks to support the research community by providing valuable data for publications, presentations, and the design of future clinical trials, while also preparing periodic reports on islet transplantation outcomes and trends. The estimated total program funding for this cooperative agreement is $700,000, with one award expected, and interested applicants are encouraged to begin forming collaborations in anticipation of the application process, which is expected to open in July 2026. For further inquiries, potential applicants can contact Thomas L. Eggerman at eggermant@extra.niddk.nih.gov or by phone at 301-594-8813.

    Point(s) of Contact
    Thomas L. Eggerman
    (301) 594-8813
    eggermant@extra.niddk.nih.gov
    Files
    No associated files provided.
    Similar Opportunities
    Notice of Intent to Publish a Funding Opportunity Announcement for Single Source for Continuation of the Integrated Islet Distribution Program (UC4)
    National Institutes of Health
    The National Institutes of Health (NIH) intends to publish a Notice of Funding Opportunity (NOFO) for a single source cooperative agreement to continue the Integrated Islet Distribution Program (IIDP), with an estimated total funding of $3.3 million. This program aims to facilitate the distribution of human islets to biomedical researchers, thereby supporting critical research in diabetes by managing islet availability, investigator eligibility, and overseeing standardized analyses of islet preparations. Interested applicants, particularly those with expertise in live cell distribution and human islet biology, are encouraged to prepare for the upcoming application process, with the estimated synopsis posting date set for June 25, 2025, and the anticipated award date on July 1, 2026. For further inquiries, potential applicants can contact Dr. Thomas L. Eggerman at eggermant@nih.gov or by phone at 301-594-8814.
    Engineering Improved Stem Cell-Derived Islet Cells for Replacement Therapies (R01 - Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Engineering Improved Stem Cell-Derived Islet Cells for Replacement Therapies (R01 - Clinical Trial Not Allowed)" aimed at advancing research in the engineering of stem cell-derived islet cells specifically for Type 1 Diabetes therapies. This grant seeks to support studies that enhance the intrinsic characteristics of these islet cell products, which are derived from well-defined cell bank sources, to improve graft viability and function through optimized banking, manufacturing, and quality control processes. With an estimated total program funding of $3 million and an award ceiling of $500,000, the NIH anticipates awarding approximately six grants, with applications due by March 7, 2026. For further inquiries, interested applicants can contact Albert Hwa at NIDDKDEM@nih.gov.
    Engineering Improved Stem Cell-Derived Islet Cells for Replacement Therapies
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a grant opportunity titled "Engineering Improved Stem Cell-Derived Islet Cells for Replacement Therapies," aimed at advancing research in stem cell-derived islet cell products for enhanced cell replacement therapy outcomes. This initiative seeks to stimulate studies focused on engineering the inherent characteristics of these products, which are derived from well-defined cell bank sources, to improve graft viability and function, particularly in the context of type 1 diabetes. The estimated total program funding is $3 million, with approximately six awards expected, and interested applicants are encouraged to prepare collaborative proposals ahead of the anticipated Notice of Funding Opportunity (NOFO) release on August 1, 2025. For further inquiries, potential applicants can contact Dr. Albert J. Hwa at albert.hwa@nih.gov or by phone at 301-451-1525.
    Notice of Intent to Publish a Funding Opportunity Announcement for Diabetes Research Centers (P30 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) intends to publish a Notice of Funding Opportunity (NOFO) for Diabetes Research Centers (P30 Clinical Trial Optional), aimed at enhancing research collaboration and innovation in diabetes and related metabolic disorders. This initiative seeks to establish a community of preclinical and clinical researchers, providing access to specialized resources and a Pilot and Feasibility Program to foster significant advancements beyond individual project capabilities. With an estimated total program funding of $18.2 million and an award ceiling of $1 million, the NIH anticipates making approximately seven awards, encouraging applications from a diverse range of eligible entities, including non-domestic institutions and community-based organizations. Interested parties should prepare for the application process, as the estimated synopsis post date is July 30, 2025, with applications expected to be solicited by March 11, 2026, and awards anticipated by December 30, 2026. For further inquiries, contact Dr. Christopher J. Lynch at lynchcj@nih.gov or call 301-325-4232.
    Collaborative Research Using Biosamples and/or Data from Type 1 Diabetes Clinical Studies (R01 - Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) for collaborative research projects focused on type 1 diabetes, specifically utilizing biosamples and data from established clinical studies. The objective is to advance the understanding of the disease's etiology and pathogenesis, with funding available for studies that aim to explore disease mechanisms, delay onset, and improve prevention strategies. A total of $5.5 million is committed for up to four awards in Fiscal Years 2026 and 2027, with application deadlines beginning on May 26, 2025, and a final submission date of March 9, 2026. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Notice of Intent to Publish a Funding Opportunity Announcement for Single Source for Continuation of the Environmental Determinants of Diabetes in The Young Study (TEDDY) Data Coordinating Center (U01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is announcing a funding opportunity for a single source cooperative agreement to support the continuation of the Environmental Determinants of Diabetes in The Young (TEDDY) Data Coordinating Center (DCC). This funding aims to facilitate the ongoing analysis of samples from a second case-control cohort and to provide resources for the closeout of the TEDDY study, which is crucial for understanding the prevention and treatment of type 1 diabetes. The total estimated funding for this opportunity is $6 million, with one award anticipated, and interested applicants can reach out to Dr. Arthur Castle at castlea@niddk.nih.gov or by phone at 301-594-7719 for further information. The estimated synopsis post date is September 26, 2025, with a closing date of October 26, 2025, and the project is expected to commence on July 1, 2026.
    Diabetes Research Centers (P30 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the Diabetes Research Centers (P30 Clinical Trial Optional) grant, aimed at enhancing national research efforts in diabetes and related diseases. This funding opportunity encourages collaboration among basic and clinical investigators by providing shared technical resources and a Pilot and Feasibility Program, with a focus on innovative approaches and synergies with other NIDDK-funded programs. Eligible applicants include various higher education institutions, nonprofits, and government entities, with a maximum funding amount of $1 million per year, and a total estimated program funding of $18.2 million for approximately seven awards. Interested parties should note that the application deadline is January 27, 2027, and can reach out to the Division of Diabetes, Endocrinology and Metabolic Diseases at NIDDKDEM@nih.gov for further information.
    Notice of Intent to Publish a Funding Opportunity Announcement for Precision Medicine for Type 1 Diabetic Nephropathy (U01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) for a cooperative agreement aimed at advancing research on Type 1 Diabetic nephropathy (T1D). This initiative seeks applications from Recruitment Sites (RS) to enroll adult and pediatric patients with T1D, particularly those at high risk for diabetic nephropathy, into a longitudinal cohort study, which will include protocol-based kidney biopsies. The research will leverage existing resources from the Kidney Precision Medicine Project (KPMP) to create a Kidney Tissue Atlas, identify disease subgroups, and explore novel therapeutic targets. The estimated total program funding for this opportunity is $1.3 million, with the NOFO expected to be published in fall 2024 and applications due in late fall 2024. Interested applicants are encouraged to reach out to the NIDDK contacts provided in the announcement for further information.
    NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for investigator-initiated, high-risk multi-center clinical trials through the Notice of Funding Opportunity (NOFO) PA-25-147. This cooperative agreement (U01) aims to support innovative studies that address critical health issues related to diabetes, digestive diseases, and kidney conditions, requiring proposals to be hypothesis-driven and operationally classified as high-risk. The program emphasizes the importance of diverse perspectives in research and mandates that planning activities be completed prior to application submission. Interested applicants should note that the application period opens on January 3, 2025, with a submission deadline of November 5, 2026. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Continuation of the Cardiovascular Repository for-Type 1 Diabetes (CARE-T1D) Consortium U01 (Open Competition)- Research
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for the continuation of the Cardiovascular Repository for-Type 1 Diabetes (CARE-T1D) Consortium through a cooperative agreement. This initiative aims to advance research on cardiovascular disease in individuals with type 1 diabetes by soliciting applications for discovery and mechanistic studies, leveraging the resources of the existing CARE-T1D consortium formed in 2024. The program is particularly focused on hypothesis-driven research utilizing multi-omics and molecular approaches, encouraging collaboration among experts in related fields such as type 2 diabetes and atherosclerosis. The estimated total funding for this program is $4.5 million, with approximately eight awards expected to be made. Interested applicants can reach out to Dr. Chandima Nishadi De Abrew Rajapakse at Chandima.rajapakse@nih.gov or by phone at 240-429-5197. The application process is set to open with a synopsis posting on April 1, 2026, and will close on July 1, 2026, with awards anticipated by March 1, 2027.